Literature DB >> 18566015

Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells.

Giovanni M Pitari1, Jieru E Lin, Fawad J Shah, Wilhelm J Lubbe, David S Zuzga, Peng Li, Stephanie Schulz, Scott A Waldman.   

Abstract

Guanylyl cyclase C (GCC), the receptor for diarrheagenic bacterial heat-stable enterotoxins (STs), inhibits colorectal cancer cell proliferation by co-opting Ca(2+) as the intracellular messenger. Similarly, extracellular Ca(2+) (Ca(2+)(o)) opposes proliferation and induces terminal differentiation in intestinal epithelial cells. In that context, human colon cancer cells develop a phenotype characterized by insensitivity to cytostasis imposed by Ca(2+)(o). Here, preconditioning with ST, mediated by GCC signaling through cyclic nucleotide-gated channels, restored Ca(2+)(o)-dependent cytostasis, reflecting posttranscriptional regulation of calcium-sensing receptors (CaRs). ST-induced GCC signaling deployed CaRs to the surface of human colon cancer cells, whereas elimination of GCC signaling in mice nearly abolished CaR expression in enterocytes. Moreover, ST-induced Ca(2+)(o)-dependent cytostasis was abrogated by CaR-specific antisense oligonucleotides. Importantly, following ST preconditioning, newly expressed CaRs at the cell surface represented tumor cell receptor targets for antiproliferative signaling by CaR agonists. Since expression of the endogenous paracrine hormones for GCC is uniformly lost early in carcinogenesis, these observations offer a mechanistic explanation for the Ca(2+)(o)-resistant phenotype of colon cancer cells. Restoration of antitumorigenic CaR signaling by GCC ligand replacement therapy represents a previously unrecognized paradigm for the prevention and treatment of human colorectal cancer employing dietary Ca(2+) supplementation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566015      PMCID: PMC2516491          DOI: 10.1093/carcin/bgn148

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  52 in total

Review 1.  Guanylyl cyclases and signaling by cyclic GMP.

Authors:  K A Lucas; G M Pitari; S Kazerounian; I Ruiz-Stewart; J Park; S Schulz; K P Chepenik; S A Waldman
Journal:  Pharmacol Rev       Date:  2000-09       Impact factor: 25.468

2.  Inhibition of store-operated calcium entry contributes to the anti-proliferative effect of non-steroidal anti-inflammatory drugs in human colon cancer cells.

Authors:  H Weiss; A Amberger; M Widschwendter; R Margreiter; D Ofner; P Dietl
Journal:  Int J Cancer       Date:  2001-06-15       Impact factor: 7.396

3.  Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells.

Authors:  G M Pitari; M D Di Guglielmo; J Park; S Schulz; S A Waldman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

4.  Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays.

Authors:  D A Notterman; U Alon; A J Sierk; A J Levine
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

5.  A Western-style diet induces benign and malignant neoplasms in the colon of normal C57Bl/6 mice.

Authors:  H L Newmark; K Yang; M Lipkin; L Kopelovich; Y Liu; K Fan; H Shinozaki
Journal:  Carcinogenesis       Date:  2001-11       Impact factor: 4.944

Review 6.  Preclinical and early human studies of calcium and colon cancer prevention.

Authors:  M Lipkin
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

7.  Dietary calcium and growth modulation of human colon cancer cells: role of the extracellular calcium-sensing receptor.

Authors:  E Kállay; E Bajna; F Wrba; S Kriwanek; M Peterlik; H S Cross
Journal:  Cancer Detect Prev       Date:  2000

8.  Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP.

Authors:  K Shailubhai; H H Yu; K Karunanandaa; J Y Wang; S L Eber; Y Wang; N S Joo; H D Kim; B W Miedema; S Z Abbas; S S Boddupalli; M G Currie; L R Forte
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

9.  Gene expression in colorectal cancer.

Authors:  Karin Birkenkamp-Demtroder; Lise Lotte Christensen; Sanne Harder Olesen; Casper M Frederiksen; Päivi Laiho; Lauri A Aaltonen; Søren Laurberg; Flemming B Sørensen; Rikke Hagemann; Torben F ØRntoft
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

10.  Involvement of calcium-sensing receptor in osteoblastic differentiation of mouse MC3T3-E1 cells.

Authors:  Mika Yamauchi; Toru Yamaguchi; Hiroshi Kaji; Toshitsugu Sugimoto; Kazuo Chihara
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-11-16       Impact factor: 4.310

View more
  11 in total

1.  Molecular staging estimates occult tumor burden in colorectal cancer.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  Adv Clin Chem       Date:  2010       Impact factor: 5.394

Review 2.  Molecular staging individualizing cancer management.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  J Surg Oncol       Date:  2012-04-01       Impact factor: 3.454

Review 3.  GUCY2C molecular staging personalizes colorectal cancer patient management.

Authors:  Jian P Gong; Stephanie Schulz; Terry Hyslop; Scott A Waldman
Journal:  Biomark Med       Date:  2012-06       Impact factor: 2.851

Review 4.  Receptor Guanylyl Cyclase C and Cyclic GMP in Health and Disease: Perspectives and Therapeutic Opportunities.

Authors:  Hari Prasad; John Kandam Kulathu Mathew; Sandhya S Visweswariah
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

5.  Receptor guanylyl cyclase C (GC-C): regulation and signal transduction.

Authors:  Nirmalya Basu; Najla Arshad; Sandhya S Visweswariah
Journal:  Mol Cell Biochem       Date:  2009-12-04       Impact factor: 3.396

6.  GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  Expert Rev Mol Diagn       Date:  2009-11       Impact factor: 5.225

Review 7.  Cure and curse: E. coli heat-stable enterotoxin and its receptor guanylyl cyclase C.

Authors:  Philipp R Weiglmeier; Paul Rösch; Hanna Berkner
Journal:  Toxins (Basel)       Date:  2010-08-26       Impact factor: 4.546

8.  The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease.

Authors:  Øystein Brenna; Torunn Bruland; Marianne W Furnes; Atle van Beelen Granlund; Ignat Drozdov; Johanna Emgård; Gunnar Brønstad; Mark Kidd; Arne K Sandvik; Björn I Gustafsson
Journal:  Scand J Gastroenterol       Date:  2015-05-15       Impact factor: 2.423

Review 9.  Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis.

Authors:  Giovanni M Pitari
Journal:  Drug Des Devel Ther       Date:  2013-04-19       Impact factor: 4.162

Review 10.  Cyclic nucleotides, gut physiology and inflammation.

Authors:  Hari Prasad; Avinash Ravindranath Shenoy; Sandhya Srikant Visweswariah
Journal:  FEBS J       Date:  2020-01-14       Impact factor: 5.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.